Athena Athena

X
[{"orgOrder":0,"company":"3B Pharmaceuticals","sponsor":"Debiopharm","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Debiopharm Expands Its Radiopharmaceutical Footprint with an Exclusive In-Licensing Agreement","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"GERMANY","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"March 2020","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery"},{"orgOrder":0,"company":"3B Pharmaceuticals","sponsor":"Clovis Oncology","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Clovis Oncology Submits IND for Novel Peptide-Targeted Radionuclide FAP-2286 for Therapeutic and Imaging Clinical Trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"GERMANY","productType":"Peptide","productStatus":"New Molecular Entity","date":"December 2020","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling"},{"orgOrder":0,"company":"3B Pharmaceuticals","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"D","amount":"$465.0 million","upfrontCash":"$40.0 million","newsHeadline":"3B Pharmaceuticals Enters Into a Global Exclusive Licensing Agreement for Its FAP-Targeting Peptide Technology","therapeuticArea":"Technology","highestDevelopmentStatus":"Discovery Platform","country":"GERMANY","productType":"Peptide","productStatus":"Undisclosed","date":"April 2023","url1":"","url2":"","graph1":"Technology","graph2":"Discovery Platform"},{"orgOrder":0,"company":"3B Pharmaceuticals","sponsor":"RefleXion Medical","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"RefleXion Acquires Global Rights to Radiopharmaceutical Molecule from 3B Pharmaceuticals to Treat High Unmet Need Cancers Including Brain, Pancreatic and Liver","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"GERMANY","productType":"Peptide","productStatus":"New Molecular Entity","date":"September 2023","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical"}]

Find Clinical Drug Pipeline Developments & Deals by 3B Pharmaceuticals

Menu
Loading...
Filters Filter
×
FILTER:
filter Company
    filter Sponsor
      filter Country
        filter Therapeutic Area
          filter Study Phase

            Active Filter(s):

            Companies By Therapeutic Area

            Development Status

            Details:

            Under the agreement, RefleXion to develop and commercialize a specific 3BP molecule, RXM-4768 which targets fibroblast activation protein (FAP) found in nearly all solid tumor types, to direct its SCINTIX™ biology-guided radiotherapy.

            Lead Product(s): RXM-4768

            Therapeutic Area: Oncology Product Name: RXM-4768

            Highest Development Status: Preclinical Product Type: Peptide

            Partner/Sponsor/Collaborator: RefleXion Medical

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Licensing Agreement September 20, 2023

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            The agreement gives Novartis exclusive worldwide rights to develop and commercialize therapeutic and imaging applications for 3BP's FAP-targeting peptide technology, including FAP-2286.

            Lead Product(s): FAP-2286

            Therapeutic Area: Technology Product Name: FAP-2286

            Highest Development Status: Discovery Platform Product Type: Peptide

            Partner/Sponsor/Collaborator: Novartis Pharmaceuticals Corporation

            Deal Size: $465.0 million Upfront Cash: $40.0 million

            Deal Type: Licensing Agreement April 24, 2023

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            Following clearance of the INDs by FDA, Clovis plans to initiate a Phase 1/2 clinical trial of lutetium-177 labeled FAP-2286 to determine the dose and tolerability of the FAP-targeting therapeutic agent, with expansion cohorts planned in multiple tumor types.

            Lead Product(s): 177Lu-FAP-2286

            Therapeutic Area: Oncology Product Name: 177Lu-FAP-2286

            Highest Development Status: IND Enabling Product Type: Peptide

            Recipient: Clovis Oncology

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable December 29, 2020

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            This agreement extends the radio-oncology portfolio of Debiopharm which currently includes another clinical stage radiotherapeutic and the radiotherapyenhancing antagonist of IAPs.

            Lead Product(s): Debio 0228

            Therapeutic Area: Oncology Product Name: Undisclosed

            Highest Development Status: Discovery Product Type: Undisclosed

            Partner/Sponsor/Collaborator: Debiopharm

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Licensing Agreement March 25, 2020

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity
            Post Enquiry
            POST ENQUIRY